NYK 1001Alternative Names: NNYK-1001; NYK-1001
Latest Information Update: 04 Jun 2015
At a glance
- Originator Nyken
- Class Antiarrhythmics
- Mechanism of Action Heat-shock protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 11 Jan 2011 NYK 1001 is available for licensing as of 11 Jan 2011. http://www.nyken.com